Nearly one in six people worldwide needlessly suffer from neglected tropical diseases (NTDs), yet a tremendous need for research and development of new products to treat and protect against these debilitating diseases still exists.

Michael Posner Joins Sabin Vaccine Institute’s Board of Trustees

WASHINGTON, DC – October 21, 2013 – The Sabin Vaccine Institute today announced the election to its Board of Trustees of Michael H. Posner, Professor of Business and Society at New York University’s Stern School of Business. For more than three decades, Mr. Posner has advanced the causes of inclusive global human rights, dignity, freedom and justice.

Dr. Albert B. Sabin is best known for developing the oral live virus polio vaccine, but his legacy extends far beyond this single groundbreaking medical advancement.

New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Pages

Subscribe to RSS - Sabin Vaccine Development